CN105073714A - 迫位原醇 - Google Patents

迫位原醇 Download PDF

Info

Publication number
CN105073714A
CN105073714A CN201380067618.3A CN201380067618A CN105073714A CN 105073714 A CN105073714 A CN 105073714A CN 201380067618 A CN201380067618 A CN 201380067618A CN 105073714 A CN105073714 A CN 105073714A
Authority
CN
China
Prior art keywords
alkyl
compounds according
pharmaceutically acceptable
independently
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380067618.3A
Other languages
English (en)
Chinese (zh)
Inventor
T·A·乔丹
J·C·査巴拉
凌克青
W·A·肯尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aldeyra Therapeutics Inc
Original Assignee
Aldexa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldexa Therapeutics Inc filed Critical Aldexa Therapeutics Inc
Publication of CN105073714A publication Critical patent/CN105073714A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
CN201380067618.3A 2012-12-20 2013-12-19 迫位原醇 Pending CN105073714A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740197P 2012-12-20 2012-12-20
US61/740,197 2012-12-20
PCT/US2013/076592 WO2014100425A1 (en) 2012-12-20 2013-12-19 Peri-carbinols

Publications (1)

Publication Number Publication Date
CN105073714A true CN105073714A (zh) 2015-11-18

Family

ID=50979217

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380067618.3A Pending CN105073714A (zh) 2012-12-20 2013-12-19 迫位原醇

Country Status (14)

Country Link
US (1) US9604997B2 (enExample)
EP (1) EP2935220A4 (enExample)
JP (1) JP2016503797A (enExample)
KR (1) KR20150118106A (enExample)
CN (1) CN105073714A (enExample)
AU (1) AU2013361314A1 (enExample)
CA (1) CA2896032A1 (enExample)
CL (1) CL2015001754A1 (enExample)
HK (1) HK1217325A1 (enExample)
IL (1) IL239178A0 (enExample)
MX (1) MX2015007916A (enExample)
RU (1) RU2015120478A (enExample)
SG (1) SG11201504859YA (enExample)
WO (1) WO2014100425A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
RU2015126015A (ru) 2013-01-25 2017-03-03 Альдейра Терапьютикс, Инк. Новые улавливатели в лечении макулодистрофии
CA2996183A1 (en) * 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
KR20180073553A (ko) * 2015-08-21 2018-07-02 알데이라 테라퓨틱스, 아이엔씨. 알데히드 접합체 및 이의 용도
KR20180116416A (ko) 2016-02-28 2018-10-24 알데이라 테라퓨틱스, 아이엔씨. 사이클로덱스트린으로의 알레르기성 안질환의 치료
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
EP3500256A4 (en) * 2016-08-22 2020-01-08 Aldeyra Therapeutics, Inc. ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF
JP7648117B2 (ja) 2017-03-16 2025-03-18 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
CA3113462A1 (en) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations of reproxalap for the treatment of dry eye disease
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
AU2021308209A1 (en) 2020-07-16 2023-02-09 Dermavant Sciences GmbH Isoquinoline compounds and their use in treating ahr imbalance

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101048384A (zh) * 2004-10-28 2007-10-03 默克公司 促代谢型谷氨酸盐受体的嘧啶和喹啉增效剂
CN101321742A (zh) * 2005-05-26 2008-12-10 神经元系统公司 用于治疗视网膜疾病的组合物和方法
CN101534826A (zh) * 2006-04-14 2009-09-16 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性（amd）的方法
CN101611009A (zh) * 2006-07-25 2009-12-23 伊维沃制药股份有限公司 喹啉衍生物
WO2010133672A1 (en) * 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
SU509046A1 (ru) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
CA2054339C (en) 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
CA2261916A1 (en) 1996-08-01 1998-02-12 Dowelanco Llc 4-substituted quinoline derivatives having fungicidal activity
AU8330898A (en) 1997-05-02 1998-11-27 Schering Aktiengesellschaft Substituted heterocycles and their use in medicaments
KR20010041811A (ko) 1998-03-12 2001-05-25 온토젠 코포레이션 단백질 티로신 포스파타제의 조절제
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
WO2001041757A1 (en) 1999-12-10 2001-06-14 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040242704A1 (en) 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
CA2527175A1 (en) 2003-04-18 2004-10-28 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
JP4975440B2 (ja) 2003-11-20 2012-07-11 オセラ・ホールディング・インコーポレイテッド 黄斑変性およびその他の眼科疾患の改善
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
KR20060135819A (ko) 2004-02-17 2006-12-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 황반변성을 포함하는 안과질환의 관리
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CA2701116C (en) 2007-10-05 2013-02-05 Acucela Inc. Alkoxy compounds for disease treatment
RU2011109190A (ru) 2008-08-12 2012-09-20 Сертрис Фармасьютикалз, Инк. (Us) Бензоксазолы, бензтиазолы и родственные аналоги в качестве модуляторов сиртуина
EP2477594A4 (en) 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
ES2620606T3 (es) 2011-01-12 2017-06-29 Ventirx Pharmaceuticals, Inc. Benzoazepinas sustituidas como moduladores de receptores tipo Toll
US9302013B2 (en) 2011-01-31 2016-04-05 Termira Ab Active principle for mitigating undesired medical conditions
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
RU2015126015A (ru) 2013-01-25 2017-03-03 Альдейра Терапьютикс, Инк. Новые улавливатели в лечении макулодистрофии
EP3151818A4 (en) 2014-06-04 2018-05-30 Case Western Reserve University Compositions and methods of treating diabetic retinopathy
US10363231B2 (en) 2014-11-24 2019-07-30 Case Western Reserve University Compounds and methods of treating ocular disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101048384A (zh) * 2004-10-28 2007-10-03 默克公司 促代谢型谷氨酸盐受体的嘧啶和喹啉增效剂
CN101321742A (zh) * 2005-05-26 2008-12-10 神经元系统公司 用于治疗视网膜疾病的组合物和方法
CN101534826A (zh) * 2006-04-14 2009-09-16 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性（amd）的方法
CN101611009A (zh) * 2006-07-25 2009-12-23 伊维沃制药股份有限公司 喹啉衍生物
WO2010133672A1 (en) * 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHENGSEN TIAN，等: "First total synthesis and determination of the absolute configuration of 1-N-methyl-3-methylamino-[N-butanoicacid-3-(9-methyl-8-propen-7-one)-amide]-benzo[f][1,7]naphthyridine-2-one, a novel benzonaphthyridine alkaloid", 《TETRAHEDRON LETTERS》 *
SCOTT E. WOLKENBERG，等: "Design, Synthesis, and Evaluation of Novel 3,6-Diaryl-4-aminoalkoxyquinolines as Selective Agonists of Somatostatin Receptor Subtype 2", 《J. MED. CHEM.》 *

Also Published As

Publication number Publication date
EP2935220A4 (en) 2016-04-27
WO2014100425A1 (en) 2014-06-26
EP2935220A1 (en) 2015-10-28
JP2016503797A (ja) 2016-02-08
US20150344432A1 (en) 2015-12-03
MX2015007916A (es) 2016-04-07
SG11201504859YA (en) 2015-07-30
KR20150118106A (ko) 2015-10-21
AU2013361314A1 (en) 2015-07-02
IL239178A0 (en) 2015-07-30
HK1217325A1 (zh) 2017-01-06
CL2015001754A1 (es) 2015-11-06
CA2896032A1 (en) 2014-06-26
US9604997B2 (en) 2017-03-28
RU2015120478A (ru) 2017-01-25

Similar Documents

Publication Publication Date Title
CN105073714A (zh) 迫位原醇
JP5042215B2 (ja) 網膜疾患を処置するための組成物および方法
JP6266023B2 (ja) 黄斑変性症の処置における新規トラップ
CA2923269C (en) Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
CN105189452B (zh) 苯基亚甲基胍衍生物以及其用于蛋白质错误折叠疾病的治疗用途
WO2010129467A1 (en) Compounds and methods for inhibition of renin, and indications therefor
EP0503349B1 (en) Hydrazone derivatives, their preparation and use
AU735767B2 (en) 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists
TW200831510A (en) Compounds
EP1723105B1 (en) Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
JP5006505B2 (ja) 緑内障および近視を処置するためのベンゾ［ｇ］キノリン誘導体
CA2612109A1 (en) Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists
US10519105B2 (en) KCNQ2-5 channel activator
US7482344B2 (en) Tricyclic steroid hormone nuclear receptor modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1217325

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151118

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1217325

Country of ref document: HK